Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon versus placebo for weight loss in advanced pancreatic cancer
ACTRN12612000299808Phase 2Terminated
- Sponsor
- Calvary Mater Newcastle
- Start
- May 2012
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC) comparing Creon with Placebo (2 arms). Primary endpoint: Change in weight. Started May 2012; status: terminated.
02
Drugs
pancreatin
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12612000299808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000299808.